Daxor Reports 45% Revenue Growth, NAV Per Share Hits $9.07 After FDA Clearance
Operating revenues rose 45% year-over-year for fiscal 2025, driven by sales of single-use diagnostic kits and military contracts, while net asset value per share surged $1.82 to $9.07. FDA 510(k) clearance for its next-generation portable Blood Volume Analyzer and a $9 million direct offering position the company for accelerated commercialization.
1. FDA Clearance & Next-Generation Analyzer
In August 2025 the company received FDA 510(k) clearance for its next-generation rapid, compact, portable Blood Volume Analyzer developed under a Department of Defense contract. This model delivers lab-grade precision three times faster than previous units, and Daxor is using new capital to assemble units while expanding its commercial sales team to meet strong market demand.
2. Fiscal 2025 Financial Performance
For the year ended December 31, 2025, operating revenues rose 45% year-over-year, driven by single-use diagnostic kit and military contract sales. Total net assets climbed over $10 million to $45.9 million, lifting net asset value per share by $1.82 to $9.07, while operating loss narrowed to $268,598 from $1.6 million in 2024.
3. Capital Raise & Regulatory Reporting Transition
In January 2026 the company closed a $9 million registered direct offering at $11.75 per share to fund commercialization efforts. The firm also plans to transition its reporting framework to the Securities Exchange Act of 1934, providing investors with standardized GAAP disclosures comparable to high-growth peers.